FY2024 Earnings Forecast for CRVS Issued By HC Wainwright

Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) – Stock analysts at HC Wainwright issued their FY2024 EPS estimates for Corvus Pharmaceuticals in a report released on Thursday, January 2nd. HC Wainwright analyst S. Lee anticipates that the company will earn ($0.41) per share for the year. HC Wainwright currently has a “Buy” rating and a $11.00 target price on the stock. The consensus estimate for Corvus Pharmaceuticals’ current full-year earnings is ($0.68) per share. HC Wainwright also issued estimates for Corvus Pharmaceuticals’ Q1 2025 earnings at ($0.10) EPS, Q2 2025 earnings at ($0.11) EPS, Q3 2025 earnings at ($0.11) EPS, Q4 2025 earnings at ($0.11) EPS, FY2025 earnings at ($0.44) EPS, FY2026 earnings at ($0.41) EPS, FY2027 earnings at ($0.31) EPS and FY2028 earnings at $0.14 EPS.

Several other research analysts also recently weighed in on the stock. StockNews.com downgraded shares of Corvus Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Thursday, October 31st. Mizuho upgraded shares of Corvus Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a report on Tuesday, October 22nd. LADENBURG THALM/SH SH boosted their price objective on Corvus Pharmaceuticals from $12.00 to $21.00 and gave the stock a “buy” rating in a report on Monday, September 16th. Finally, Oppenheimer raised their target price on Corvus Pharmaceuticals from $8.00 to $14.00 and gave the company an “outperform” rating in a report on Wednesday, November 13th. One investment analyst has rated the stock with a sell rating, four have given a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, Corvus Pharmaceuticals presently has an average rating of “Moderate Buy” and an average target price of $12.38.

Corvus Pharmaceuticals Stock Performance

Shares of Corvus Pharmaceuticals stock opened at $5.75 on Monday. Corvus Pharmaceuticals has a 52 week low of $1.30 and a 52 week high of $10.00. The stock has a 50 day moving average price of $7.62 and a two-hundred day moving average price of $5.36. The stock has a market capitalization of $369.48 million, a PE ratio of -6.18 and a beta of 1.07.

Hedge Funds Weigh In On Corvus Pharmaceuticals

Hedge funds and other institutional investors have recently modified their holdings of the business. Nwam LLC bought a new stake in Corvus Pharmaceuticals during the third quarter worth $53,000. XTX Topco Ltd purchased a new stake in shares of Corvus Pharmaceuticals during the 3rd quarter valued at $74,000. Virtu Financial LLC bought a new stake in shares of Corvus Pharmaceuticals during the 3rd quarter worth $83,000. Avity Investment Management Inc. raised its stake in shares of Corvus Pharmaceuticals by 138.2% during the 3rd quarter. Avity Investment Management Inc. now owns 27,580 shares of the company’s stock worth $146,000 after purchasing an additional 16,000 shares during the period. Finally, Oppenheimer & Co. Inc. purchased a new position in shares of Corvus Pharmaceuticals in the 3rd quarter worth about $89,000. Hedge funds and other institutional investors own 46.64% of the company’s stock.

About Corvus Pharmaceuticals

Corvus Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, focuses on the development and commercialization of immune modulator product candidates to treat solid cancers, T cell lymphomas, autoimmune, allergic, and infectious diseases. Its lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell lymphoma, solid tumors, and atopic dermatitis.